Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer.

Hsiao SH, Lin SE, Chou YT, Wang JL, Chung CL, Yu MC, Fang CL, Lee HL, Chiang LL, Liu HE, Wu CW.

Mol Clin Oncol. 2014 Mar;2(2):252-258. Epub 2013 Dec 23.

PMID:
24649342
[PubMed]
Free PMC Article
2.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC.

J Thorac Oncol. 2014 Feb;9(2):154-62. doi: 10.1097/JTO.0000000000000033.

PMID:
24419411
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.

Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GA.

Diagn Pathol. 2013 Dec 10;8:201. doi: 10.1186/1746-1596-8-201.

PMID:
24326178
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.

Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedeutour F, Karayan-Tapon L.

Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23.

PMID:
23930206
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Second-Line Therapy for Advanced NSCLC.

Weiss JM, Stinchcombe TE.

Oncologist. 2013;18(8):947-53. doi: 10.1634/theoncologist.2013-0096. Epub 2013 Aug 5. Review.

PMID:
23918070
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC).

Furrukh M, Al-Moundhri M, Zahid KF, Kumar S, Burney I.

Sultan Qaboos Univ Med J. 2013 May;13(2):202-17. Epub 2013 May 9.

PMID:
23862025
[PubMed]
Free PMC Article
7.

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C.

Clin Lung Cancer. 2013 Sep;14(5):581-91. doi: 10.1016/j.cllc.2013.05.002. Epub 2013 Jul 1.

PMID:
23827517
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C.

Lung Cancer. 2013 Sep;81(3):347-53. doi: 10.1016/j.lungcan.2013.05.011. Epub 2013 Jun 24.

PMID:
23806795
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

How and when to use genetic markers for nonsmall cell lung cancer.

Lazarus DR, Ost DE.

Curr Opin Pulm Med. 2013 Jul;19(4):331-9. doi: 10.1097/MCP.0b013e328362075c. Review.

PMID:
23715289
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.

Shim HS, Chung JH, Kim L, Chang S, Kim WS, Lee GK, Jung SH, Jang SJ.

Korean J Pathol. 2013 Apr;47(2):100-6. doi: 10.4132/KoreanJPathol.2013.47.2.100. Epub 2013 Apr 24.

PMID:
23667368
[PubMed]
Free PMC Article
11.

Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.

Wen YH, Brogi E, Hasanovic A, Ladanyi M, Soslow RA, Chitale D, Shia J, Moreira AL.

Mod Pathol. 2013 Sep;26(9):1197-203. doi: 10.1038/modpathol.2013.53. Epub 2013 Apr 19.

PMID:
23599147
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research.

Lynch JA, Khoury MJ, Borzecki A, Cromwell J, Hayman LL, Ponte PR, Miller GA, Lathan CS.

Genet Med. 2013 Aug;15(8):630-8. doi: 10.1038/gim.2013.5. Epub 2013 Feb 28.

PMID:
23448725
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.

Nguyen KS, Neal JW.

Biologics. 2012;6:337-45. doi: 10.2147/BTT.S26558. Epub 2012 Sep 25.

PMID:
23055691
[PubMed]
Free PMC Article
14.

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M.

Clin Cancer Res. 2012 Nov 15;18(22):6169-77. doi: 10.1158/1078-0432.CCR-11-3265. Epub 2012 Sep 26.

PMID:
23014527
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.

Clin Cancer Res. 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. Epub 2012 Aug 23.

PMID:
22919003
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A time to test, a time to treat.

Weickhardt AJ, Doebele RC, Camidge DR.

J Thorac Dis. 2012 Apr 1;4(2):223-5. doi: 10.3978/j.issn.2072-1439.2012.03.13. No abstract available.

PMID:
22833834
[PubMed]
Free PMC Article
17.

Personalized choice of maintenance therapies in non-small-cell lung cancer.

Blais N, Corrales-Rodriguez L.

Curr Oncol. 2012 Jun;19(Suppl 1):S64-72. doi: 10.3747/co.19.1068.

PMID:
22787413
[PubMed]
Free PMC Article
18.

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Mileshkin L, Shah B, Michael M.

Chemother Res Pract. 2012;2012:838509. doi: 10.1155/2012/838509. Epub 2012 May 14.

PMID:
22666589
[PubMed]
Free PMC Article
19.

Screening for germline EGFR T790M mutations through lung cancer genotyping.

Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME.

J Thorac Oncol. 2012 Jun;7(6):1049-52. doi: 10.1097/JTO.0b013e318250ed9d. Erratum in: J Thorac Oncol. 2012 Jul;7(7):1206.

PMID:
22588155
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.

Hirsh V, Melosky B, Goss G, Morris D, Morzycki W.

Curr Oncol. 2012 Apr;19(2):78-90. doi: 10.3747/co.19.1018. Erratum in: Curr Oncol. 2012 Jun;19(3):e228.

PMID:
22514494
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk